Transfer of Part of the Blood Purification-Related Business
First written in FY2021-Q1. 1 of 6 entries say "Achieved", first in FY2021. Latest entry: FY2022.
4 other companies' latest entry also says "Other".
- FY2022The full-year revenue impact of the business transfer was quantified.Annual report
「The transfer of the blood purification business in April 2021 was a factor behind the decline in revenue.」
The transfer of the blood purification business in April 2021 was a factor behind the full-year decline in revenue in the surgical business. For the cumulative quarterly period, the company disclosed a ¥394 million year-on-year decline in revenue as the impact. - FY2022-Q3The revenue impact of the business transfer was updated.Annual report
「The transfer of the blood purification business in April 2021 was a factor behind a ¥394 million year-on-year decline in revenue.」
Regarding the transfer of the blood purification business completed in April 2021, the company quantified its impact on the nine-month cumulative results as a ¥394 million year-on-year decline in revenue. - FY2022-Q2The revenue impact following the business transfer was quantified.Annual report
「The transfer of the blood purification business in April 2021 was a factor behind the decline in revenue, with revenue from that business in the same period of the previous year amounting to ¥272 million.」
Regarding the transfer of the blood purification business completed in April 2021, the company disclosed that the previous year's revenue from the business of ¥272 million was a factor behind the decline in revenue for the current quarter. - FY2021AchievedAnnual report
「In the surgical business, we decided to transfer the blood purification business, for which no synergies with our other businesses were expected, and completed the transfer in April 2021.」
The transfer of the blood purification business was completed in April 2021 to focus management resources on areas including cardiovascular care. - FY2021-Q3Gain recorded on the transfer of part of the blood purification businessAnnual report
「The company recorded a total of ¥779 million in non-operating income, including gains on the transfer of part of the business classified as blood purification-related.」
Gains on the transfer of part of the business classified as blood purification-related were recorded in non-operating income. - FY2021-Q1First statedAnnual report
「In addition to interest and dividend income, the company recorded ¥239 million in non-operating income, including gains on the transfer of part of the business classified as blood purification-related.」
Gains on the transfer of part of the business classified as blood purification-related were recorded in non-operating income. The purpose of the transfer and details of its scope were not described in this filing.